{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:31:16Z","timestamp":1769603476322,"version":"3.49.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[1999,5,1]],"date-time":"1999-05-01T00:00:00Z","timestamp":925516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although urinary measurements of collagen degradation provide valid estimates of bone resorption, their clinical application is hampered by pronounced analytical and biological variability. Therefore, immunoassays for the determination of such parameters in serum have been developed. In this study, we assessed the performance of three new serum markers of bone turnover, i.e., C-terminal and N-terminal telopeptides of type I collagen (S-CTX and S-NTX) and bone sialoprotein. Results were compared with urinary total pyridinoline, total deoxypyridinoline, and urinary C-terminal telopeptides of type I collagen (U-CTX) and urinary N-terminal telopeptides of type I collagen (U-NTX). The study population included healthy men (n = 27), premenopausal (n = 30) and postmenopausal (n = 31) women, patients with hepatic dysfunction (HF, n = 24), renal failure (RF, n = 30), breast cancer without (BC\u2013, n = 24) and with (BC+, n = 30) bone metastases, primary vertebral osteoporosis (OPO, n = 27), primary hyperparathyroidism (PHPT, n = 16), active Paget's disease of bone (n = 18), multiple myeloma (MM, n = 18), and patients with hypercalcemia of malignancy before and after treatment with pamidronate (HOM, n = 28). Changes in urinary and serum markers were similar in most metabolic bone diseases. However, differentiation between healthy controls and OPO, or PHPT, was improved by the serum markers. In MM, all serum and urinary markers were elevated (p &amp;lt; 0.05 vs. controls). In BC+, skeletal involvement was reflected by significant increments in all indices (p &amp;lt; 0.01 vs. BC\u2013), except U-CTX and S-CTX. In HOM, pamidronate-induced changes in biomarkers were most pronounced for U-CTX and S-CTX and S-NTX. HF and RF were associated with elevated levels of all serum markers (p &amp;lt; 0.05 vs. controls). In conclusion, measurements in serum reflect bone resorption to the same extent as the urinary indices. Since serum markers circumvent some of the limitations of urinary measurements, their use potentially improves the assessment of skeletal disorders.<\/jats:p>","DOI":"10.1359\/jbmr.1999.14.5.792","type":"journal-article","created":{"date-parts":[[2006,4,26]],"date-time":"2006-04-26T20:14:41Z","timestamp":1146082481000},"page":"792-801","source":"Crossref","is-referenced-by-count":146,"title":["Novel Serum Markers of Bone Resorption: Clinical Assessment and Comparison with Established Urinary Indices"],"prefix":"10.1093","volume":"14","author":[{"given":"Henning W.","family":"Woitge","sequence":"first","affiliation":[{"name":"Department of Medicine I, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Pecherstorfer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Wilhelminenspital, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea-V.","family":"Keck","sequence":"additional","affiliation":[{"name":"Department of Medicine, Wilhelminenspital, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Horn","sequence":"additional","affiliation":[{"name":"Department of Medicine, Wilhelminenspital, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Ziegler","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus J.","family":"Seibel","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024020713374706600_bib1","first-page":"333","article-title":"Molecular basis and clinical application of biological markers of bone turnover","volume":"17","author":"Calvo","year":"1996","journal-title":"Endocr Rev"},{"key":"2024020713374706600_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/1043-2760(92)90129-O","article-title":"Urinary pyridinium crosslinks of collagen: Specific markers of bone resorption in metabolic bone disease","volume":"3","author":"Seibel","year":"1992","journal-title":"Trends Endocrinol Metab"},{"key":"2024020713374706600_bib3","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/jbmr.5650071119","article-title":"A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine","volume":"7","author":"Hanson","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024020713374706600_bib4","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/clinchem\/40.11.2022","article-title":"Evaluation of an immunoassay for quantitation of type I collagen degradation products in urine","volume":"40","author":"Bonde","year":"1994","journal-title":"Clin Chem"},{"key":"2024020713374706600_bib5","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1359\/jbmr.1998.13.7.1124","article-title":"Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability","volume":"13","author":"Hannon","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024020713374706600_bib6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/clinchem\/39.4.635","article-title":"Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation","volume":"39","author":"Risteli","year":"1993","journal-title":"Clin Chem"},{"key":"2024020713374706600_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/BF00316286","article-title":"The carboxy-terminal pyridinoline crosslinked telopeptide of type I collagen in serum as a marker of bone resorption: The effect of nandrolone decanoate and hormone replacement therapy","volume":"54","author":"Hassager","year":"1994","journal-title":"Calcif Tissue Int"},{"key":"2024020713374706600_bib8","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1359\/jbmr.1997.12.7.1028","article-title":"Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen","volume":"12","author":"Bonde","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024020713374706600_bib9","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/clinchem\/43.11.2058","article-title":"Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption","volume":"43","author":"Clemens","year":"1997","journal-title":"Clin Chem"},{"key":"2024020713374706600_bib10","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1093\/clinchem\/43.11.2076","article-title":"Improved purification of bone sialoprotein and development of a homologous radioimmunoassay","volume":"43","author":"Karmatschek","year":"1997","journal-title":"Clin Chem"},{"key":"2024020713374706600_bib11","first-page":"3289","article-title":"Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease","volume":"81","author":"Seibel","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713374706600_bib12","doi-asserted-by":"crossref","first-page":"9901","DOI":"10.1016\/S0021-9258(18)98430-9","article-title":"Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption","volume":"268","author":"Ross","year":"1993","journal-title":"J Biol Chem"},{"key":"2024020713374706600_bib13","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024020713374706600_bib14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"2024020713374706600_bib15","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1093\/clinchem\/42.11.1796","article-title":"Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorder or metabolic bone diseases","volume":"42","author":"Woitge","year":"1996","journal-title":"Clin Chem"},{"key":"2024020713374706600_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0003-2697(92)90519-D","article-title":"Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography","volume":"207","author":"Pratt","year":"1992","journal-title":"Anal Biochem"},{"key":"2024020713374706600_bib17","first-page":"344","article-title":"Eine Methode zur direkten Bestimmung des Creatinins im Serum und Urin ohne Enteiweissung nach einer spezifischen modifizierten Jaff\u00e9-Reaktion","volume":"12","author":"Helger","year":"1974","journal-title":"Z Klin Chem Klin Biochem"},{"key":"2024020713374706600_bib18","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/jbmr.5650091019","article-title":"Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption","volume":"9","author":"Robins","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024020713374706600_bib19","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/jbmr.5650090916","article-title":"Urinary hydroxypyridinium crosslinks of collagen in a population-based screening for overt vertebral osteoporosis: results of a pilot study","volume":"9","author":"Seibel","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024020713374706600_bib20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF01623829","article-title":"Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption","volume":"3","author":"Eastell","year":"1993","journal-title":"Osteoporos Int"},{"key":"2024020713374706600_bib21","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/jbmr.5650080714","article-title":"Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis","volume":"8","author":"Seibel","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024020713374706600_bib22","first-page":"1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713374706600_bib23","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(87)91671-0","article-title":"Prediction of rapid bone loss in postmenopausal women","volume":"1","author":"Christiansen","year":"1987","journal-title":"Lancet"},{"key":"2024020713374706600_bib24","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/bmj.312.7029.482","article-title":"Case control analysis of bone resorption markers, disability and hip fracture risk: The Rotterdam study","volume":"312","author":"Van Daele","year":"1996","journal-title":"BMJ"},{"key":"2024020713374706600_bib25","first-page":"481","article-title":"Urinary hydroxy-pyridinium crosslinks of collagen as specific indices of bone resorption in primary hyperparathyroidism","volume":"74","author":"Seibel","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713374706600_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0950-351X(97)80553-8","article-title":"Paget's disease of bone: Clinical, pathogenetic and therapeutic aspects","volume":"11","author":"Papapoulos","year":"1997","journal-title":"Baillieres Clin Endocrinol Metab"},{"key":"2024020713374706600_bib27","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1182\/blood.V90.9.3743","article-title":"Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: Quantification by urinary pyridnium crosslinks of collagen","volume":"9","author":"Pecherstorfer","year":"1997","journal-title":"Blood"},{"key":"2024020713374706600_bib28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0049-0172(94)90053-1","article-title":"Bisphosphonates: Pharmacology","volume":"23","author":"Fleisch","year":"1994","journal-title":"Semin Arthritis Rheum"},{"key":"2024020713374706600_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF00298992","article-title":"Acute effects of bisphosphonates on new and traditional markers of bone resorption","volume":"57","author":"Pedrazzoni","year":"1995","journal-title":"Calcif Tissue Int"},{"key":"2024020713374706600_bib30","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/clinchem\/41.11.1592","article-title":"Different responses on biochemical markers of bone resorption to bisphosphonate therapy in Paget disease","volume":"41","author":"Blumsohn","year":"1995","journal-title":"Clin Chem"},{"key":"2024020713374706600_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.5650070111","article-title":"The osteocalcin propeptide is not secreted in vivo or in vitro","volume":"7","author":"Gundberg","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024020713374706600_bib32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/rheumatology\/32.4.307","article-title":"Physiological variations in the urinary excretion of pyridinium crosslinks of collagen","volume":"32","author":"McLaren","year":"1993","journal-title":"Br J Rheumatol"},{"key":"2024020713374706600_bib33","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1359\/jbmr.1998.13.4.731","article-title":"Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis","volume":"13","author":"Gua\u00f1abens","year":"1998","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.1999.14.5.792","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/14\/5\/792\/56600614\/5650140516.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/14\/5\/792\/56600614\/5650140516.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:58:11Z","timestamp":1710341891000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/14\/5\/792-801\/7515006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,5,1]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[1999,5,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.1999.14.5.792","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1999,5,1]]},"published":{"date-parts":[[1999,5,1]]}}}